Zetta Genomics makes strategic growth hires in readiness for Series A
James Davies joins as Business Development Manager and Anna Santagostino Barbone as Technical Writer. Their appointments build out the Zetta Genomics talent bench as it unleashes the power of genomic medicine to improve health outcomes for millions of people across the globe.
Following the successful close of Zetta Genomics’ second seed funding round in February this year, the company is expanding its genomic data management capabilities, with a specific focus on customer experience and engagement.
This strategic investment enables Zetta to enhance its offerings and customer success initiatives, with objectives that include over 500,000 genomes under management, world-class talent acquisition and international expansion from Spain, the UK and the US.
James Davies joins Zetta Genomics as its new Business Development Manager. A key attribute is his deep understanding of genomics in both the academic and business contexts — to better understand customer objectives and support them to achieve research, clinical and pharma goals. He has brought his bioinformatic and translational skillset to a range of leading life science companies, including Prescient Healthcare Group, Seven Bridges Genomics and Velsera.
Anna Santagostino Barbone holds a Masters of Engineering in Bioengineering from the University of Sheffield. She joins Zetta with over five years’ experience in the medical device industry, focusing on service, support and product reliability.
Her new role includes close cooperation with engineering teams to ensure ease of accessibility – including for non-specialist users – and the application of the company’s XetaBase technology across disciplines.
She previously worked at CMR Surgical, where she led global teams and spearheaded projects that use data to optimise customer service, experience and support.
She has specialised in areas that include reliability analysis methods, problem-solving methodologies, safety risk management, quality management systems auditing, and Lean Six Sigma.
Zetta Genomics CEO, Ignacio Medina, said: “Talent drives Zetta Genomics and we focus on hires of the highest calibre. James and Anna bring us industry-leading skills as we develop and deploy our transformational XetaBase technology.
“Their expertise will be invaluable as we continue to advance our genomic data management solutions and deliver exceptional value to our customers.”
Founded in 2017, Zetta Genomics is headquartered in Cambridge with offices in Valencia. It is a spin-out from the University of Cambridge and Genomics England.
The company’s XetaBase genomic data management platform is designed to simplify tertiary genomic data analysis – aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.
